Drug intelligence / Profile preview

erythropoietin + iron supplements

Development stage
Unknown
Lead developer
Sheba Medical Center
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Oral, Intravenous
01

Overview

erythropoietin + iron supplements refers to a combination therapeutic regimen investigated by Sheba Medical Center for the management of anemia of prematurity in very low birth weight infants. Erythropoietin (EPO) is a recombinant glycoprotein that mimics the endogenous hormone produced by the kidneys, acting as an agonist at the erythropoietin receptor (EPOR) on erythroid progenitor cells to stimulate their proliferation and differentiation into mature red blood cells. Because EPO-stimulated erythropoiesis increases the demand for iron to synthesize hemoglobin, iron supplementation is co-administered to prevent iron deficiency and ensure effective red blood cell production. This specific study by Sheba Medical Center (NCT00164411) was designed to assess the safety of this regimen, particularly its potential impact on the development and progression of retinopathy of prematurity (ROP), a condition where abnormal blood vessel growth occurs in the retina.

Other names
erythropoietin and early iron supplementsEPO + ironrecombinant human erythropoietin + iron
02

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on erythropoietin + iron supplements.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythropoietin + iron supplements.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call